Full Press Release Details
Forward Looking Statements
the leader addressing
subclinical zinc deficiency
chronic copper toxicity
Copyright 2008 Pipex Pharmaceuticals, Inc.
Copyright 2008 Pipex Pharmaceuticals, Inc.
NYSE-Amex Listed: AEN
$6MM Personally Invested by Chairman
Went Public October 2006
$21MM @$2.00/share 2006-2007
Current Market Cap: $25MM @ $1.19 share
Daily Volume 725,000 shares/day
21MM Primary Outstanding Shares
+3MM Warrants & Options ($1.51 Avg. Exercise Price/Share)
$3,600,000 cash on hand 9/30/09
Average Burn Rate/Qtr. ~$790K
Adeona Corporate Overview
Copyright 2008 Pipex Pharmaceuticals, Inc.
HartLab: CLIA Certified Reference Lab 7/10/09
CopperProof Diagnostic Panel 11/9/09
Zinthionein ZC GS-150 Q1 2010
Zinc-Monocysteine GRAS
Oral Estriol for MS Phase
Oral dnaJP1 for RA Phase II Completed
Oral Flupirtine for FMS Phase II IND Approved
Copyright 2008 Pipex Pharmaceuticals, Inc.
David A. Newsome, M.D.
President, HealthMine Subsidiary
Duke University, A.B.
Columbia University, M.D.
Harvard Medical School, Ophthalmology Residency
(Massachusetts Eye and Ear Infirmary)
Harvard Medical School, Retina Disease and Surgery Fellowship
Bascom Palmer Eye Institute, Retina Disease and Surgery Fellowship
Research & Faculty Experience:
- National Eye Institute (NIH)
Chief, Retinal Disease Section
- Johns Hopkins, Wilmer Eye Institute, Associate
- LSU Eye Center, Professor
Author, 150 Peer-Reviewed Publications and 2 books
- Originated Zinc Hypothesis for Age-Related
Macular Degeneration
- 1988, Published First Clinical Trial, "Oral
Zinc Supplementation for Age Related
Macular Degeneration"
- Currently marked as "Preservision",
2008 Sales ~ $300MM, B&L and Alcon
Copyright 2008 Pipex Pharmaceuticals, Inc.
George J. Brewer, M.D.
Co-Founder, Chair SAB
Chairman Emeritus, Department of Human Genetics, University of
Foremost Authority on Chronic Copper Toxicity - Wilson's disease,
Member, EPA-Convened National Academy of Sciences -
on Copper in Drinking Water (2000)
Drawbacks of Galzin /Wilzin :
- Nausea in 90% of Patients, G.I. Irritation
- 3X/day dosing away from meals
Co-inventor, Adeona Modified-Release Oral Zinc Technology
Galzin is a registered trademark of Gate Pharmaceuticals Inc.
Copyright 2008 Pipex Pharmaceuticals, Inc.
Diseases of Confirmed or Suspected
Copper/Zinc Dyshomeostasis
| DISEASE | U.S. PERSONS |
| Wilson's Disease | 10,000 |
| Dry Age-Related Macular Degeneration | 17,000,000 |
| Alzheimer's Disease | 5,800,000 |
| Mild Cognitive Impairment | 15,000,000 |
| Parkinson's Disease | 400,000 |
| Complications of Diabetes | 23,000,000 |
| Estimated Total U.S. Persons | 50,000,000 |
"Copper" Text Added.
5.3 Million Miles of Copper Tube in U.S.
Current EPA Limit of Copper in Water:
Average Home has About 1/10th the EPA Limit
Copper-Containing Multivitamins and
Cognitive Decline in the CHAP Study (2006)
Chicago Health and Aging Project (CHAP)
3718 Chicago Residents over Age 65
Cognition Tested at 0, 3 and 6 Years
Copper-Containing Multivitamin Consumption
Consumers of Copper-Containing
2mg/day) with a High Fat
Diet had 6.51 Times the Rate of Cognitive
Decline than Persons not taking Copper-
Containing Multivitamins
Morris MC et. al., Arch. Neurol. Vol. 63;1085-8 (Aug 2006)
Chicago Health and Aging Project (CHAP)
Serum Copper Dyshomeostasis in AD & MCI
| Free Copper Ions | 0 | 0.0001 |
| Homocysteine | <10 | <0.5% |
| Ferroxidase II | <10 | <0.5% |
| Extracellular SOD | <10 | <0.5% |
| Factors V and VIII | <5 | <0.5% |
| Metallothionein | <1 | <0.1% |
| 15-60kDa Proteins | 40 | <0.5% |
| Small Peptides | 35 | <0.5% |
| Albumin | 150 | 15% |
| Ceruloplasmin | 700 | 70% |
Copyright 2007 Pipex Pharmaceuticals, Inc.
Serum Copper/Zinc Dyshomeostasis in
Elevated Percent Serum Free Copper in AD
- Distinguishes AD from Normals (Squitti
- Prognostic for Cognitive Decline (Squitti
- Correlates with Cognitive Loss (Arnal
N, et. al. Dec. 2009)
Defective Ceruloplasmin (Squitti et. al. Jan. 2008)
90 Subject Prospective, Observational, IRB-Approved
Randomized Comparative
The Alzheimer's Center at Albany Medical Center - P.I. Earl
30 Alzheimer's, 30 Parkinson's, 30 Age-Matched Normals
Patients Recruited 2007-2008. Analysis Q1 2009
Results Presented at ICAD (International Conference on
Disease) July 15, 2009
Acquisition by Adeona - July 10, 2009
CLIA-Certified Laboratory, Chicago
Launched CopperProof Panel - Nov. 2009